SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
FDA headquarters with a purple psychedelic background.
Psychedelics
Trump throws support behind psychedelics with executive order
A new executive order could usher in psychedelics as the “key next wave” of mental health therapies, according to analysts at RBC Capital Markets.
April 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Sponsored by Curium
From Product to Patient in Nuclear Medicine: Why Vertical Integration Is Essential for a Competitive Advantage
In nuclear medicine, innovation alone isn’t enough. What matters is whether it can be delivered on time, every time, because timing is critical for our patients. And that delivery promise must hold up under real-world pressure – from routine variability to sudden disruptions that can reroute global logistics overnight.
April 20, 2026
 · 
4 min read
 · 
Renaud Dehareng, CEO, Curium
Online Medicine or internet pharmacy services as a pharmacist or web doctor and medical health service or digital healthcare for purchase and delivery of medications as Telemedicine and Teleconsultations.
GLP-1
Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch
While Novo Nordisk’s Wegovy pill reached more than 3,000 patients in its first week on the market, analysts at RBC Capital Markets said a direct comparison of the two figures could be misleading given the shorter data collection time for Foundayo.
April 17, 2026
 · 
1 min read
 · 
Tristan Manalac
Concept of money prize. Vector illustration. Halftone hand holds bouquet of money flowers. Gift prize, donation, earnings, bonus or cashback concept. Retro poster or banner. Creative trend collage.
IPO
UPDATE: Kailera breaks biotech IPO record with $625M debut
Obesity-focused Kailera Therapeutics debuted on the Nasdaq Friday after raising a record $625 million, beating Moderna’s $600 million from 2018.
April 17, 2026
 · 
4 min read
 · 
Tristan Manalac
Government
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
The pharma industry “own Congress, they own the media,” Health Secretary Robert F. Kennedy, Jr. told lawmakers by way of explaining the bad press against FDA Commissioner Marty Makary following the second rejection of Replimune’s advanced melanoma drug.
April 17, 2026
 · 
2 min read
 · 
Tristan Manalac
Vector Illustration Of Athletes Running On Race Track
Obesity
Novo may have muscle advantage over Lilly in weight-loss race: preprint
More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet to be peer reviewed.
April 17, 2026
 · 
2 min read
 · 
Tristan Manalac
whistle of a soccer / football referee or coach on black board with tactical diagram
FDA
Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA
After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency’s lack of consistency. With new safety guidelines for gene editing therapies, the FDA has taken a first step toward fixing both problems.
April 17, 2026
 · 
5 min read
 · 
Heather McKenzie
Sunset illuminating the tall skyscrapers of San Diego in California from Centennial Park in Coronado
Cancer
Merck’s PD-1/VEGF data star in stacked lineup of AACR ‘26 data reveals
The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that could shape the future of ADCs, protein degraders and KRAS-targeted therapies.
April 17, 2026
 · 
5 min read
 · 
Nick Paul Taylor
Insights
Funding the future of European biotech
In this episode of Denatured, you’ll be hearing from Edoardo Negroni, co-founder & managing partner at AurorA-TT and Naveed Siddiqi, senior partner, Venture Investments at Novo Holdings. We debate whether Europe’s world-class science can be matched by a truly integrated venture ecosystem—and what it would take, in practice, to get there.
April 16, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS